Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...147148149150151152153154155156157...170171»
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Clinical, Journal:  Efficacy of rivaroxaban for pulmonary embolism. (Pubmed Central) -  May 5, 2019   
    The findings of this study will summarize updated evidence on the efficacy and safety of rivaroxaban for patients with PE.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Trial initiation date:  DOAC in Unusual Site Venous Thrombosis (clinicaltrials.gov) -  May 2, 2019   
    P=N/A,  N=100, Not yet recruiting, 
    Our "go-to" table provides a supportive tool for physicians in preventing medical errors when managing patients on oral anticoagulants. Initiation date: Jan 2019 --> Jun 2019
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Journal:  Andexanet Alfa for Reversing Factor Xa Inhibition. (Pubmed Central) -  May 2, 2019   
    Since the duration of the DOACs is much less than that of warfarin, it is unclear how many patients would actually need andexanet in clinical practice, since cessation of the DOAC may be all that is needed to effectively manage bleeding. Nonetheless, having andexanet available in cases of DOAC-associated severe or life-threatening bleeding represents a therapeutic advance and should provide an added level of comfort with the clinical use of DOACs.
  • ||||||||||  methylprednisolone / generics
    Journal:  Cerebral Venous Sinus Thrombosis in Systemic Lupus Erythematosus. (Pubmed Central) -  May 2, 2019   
    She additionally received azathioprine 50 mg tab BID...She got additional oral anticoagulant rivaroxaban 15 mg tab BID and eventually discharged...As shown in previous cases, the patient had remarkable response to high dose steroid treatment and eventually got anticoagulant after her platelet had increased. In summary, prompt diagnosis and treatment of CVST are important for a favorable prognosis.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Clinical, Review, Journal:  Rivaroxaban and the EINSTEIN clinical trial programme. (Pubmed Central) -  Apr 30, 2019   
    The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Review, Journal:  Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation. (Pubmed Central) -  Apr 28, 2019   
    Warfarin was the most commonly used oral anticoagulant, followed by apixaban, while dabigatran and rivaroxaban were rarely used. This article reviews the current evidence regarding each oral anticoagulant especially as they relate to patients with ESKD.
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  ROSE ACS: Rivaroxaban ACS Specialist Cohort Event Monitoring Study (clinicaltrials.gov) -  Apr 24, 2019   
    P=N/A,  N=701, Completed, 
    Trial completion date: Nov 2019 --> Jan 2020 | Trial primary completion date: Nov 2019 --> Jan 2020 Recruiting --> Completed | N=2386 --> 701 | Trial completion date: Sep 2018 --> Feb 2019 | Trial primary completion date: Sep 2018 --> Feb 2019
  • ||||||||||  Xarelto (rivaroxaban) / J&J
    Trial completion date, Surgery:  Utilization of TEG to Monitor Rivaroxaban Activity (clinicaltrials.gov) -  Apr 24, 2019   
    P=N/A,  N=100, Active, not recruiting, 
    Recruiting --> Completed | N=2386 --> 701 | Trial completion date: Sep 2018 --> Feb 2019 | Trial primary completion date: Sep 2018 --> Feb 2019 Trial completion date: Mar 2019 --> Sep 2019
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Journal:  Surface Acoustic Wave-Based Microfluidic Coagulation Device for Monitoring Anticoagulant Therapy. (Pubmed Central) -  Apr 23, 2019   
    Preliminary clinical data prove the suitability of the SAW-CT in patients receiving warfarin, rivaroxaban, or dabigatran. The device could be particularly useful as a point-of-care test to assess whole blood coagulation (e.g., in stroke units or in other emergency settings).
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    New P3 trial:  RISE MS: RIvoraxaban in Mitral Stenosis (clinicaltrials.gov) -  Apr 23, 2019   
    P3,  N=100, Not yet recruiting, 
  • ||||||||||  Fraxiparine (nadroparin) / Aspen
    Trial completion date, Trial primary completion date, Metastases:  Anticoagulation for Advanced Cirrhotic Patients After TIPS (clinicaltrials.gov) -  Apr 23, 2019   
    P=N/A,  N=254, Recruiting, 
    No abstract available Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Clinical, Journal:  Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus-A case series and literature review. (Pubmed Central) -  Apr 23, 2019   
    Direct oral anticoagulants, in particular Dabigatran and Rivaroxaban have been proved to be effective in preventing thromboembolism among patients with non-valvular atrial fibrillation...Use of direct oral anticoagulants showed promising results in the resolution of left ventricular thrombus in patients diagnosed with left ventricular thrombus. Further studies at multiple health care centers are needed to further evaluate the efficacy and safety of direct oral anticoagulants as compared to traditional treatment in patients with left ventricular thrombus.